Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

36.54USD
12 Jan 2018
Change (% chg)

$-0.02 (-0.05%)
Prev Close
$36.56
Open
$36.61
Day's High
$36.80
Day's Low
$36.46
Volume
5,226,162
Avg. Vol
5,045,230
52-wk High
$37.35
52-wk Low
$30.90

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $214,682.30
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.55

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.44
EPS (TTM): -- -- --
ROI: -- 14.85 10.61
ROE: -- 16.31 14.21

BRIEF-Novartis poaches Pfizer oncology head Elizabeth Barrett

* Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the Executive Committee of Novartis, effective February 1, 2018

11 Jan 2018

BRIEF-Basilea Announces Completion Of License Agreement Extension With Pfizer

* BASILEA ANNOUNCES COMPLETION OF THE LICENSE AGREEMENT EXTENSION WITH PFIZER FOR ANTIFUNGAL CRESEMBA FOR CHINA AND ASIA PACIFIC Source text for Eikon: Further company coverage: (Gdynia Newsroom)

10 Jan 2018

GSK CEO says looking at Pfizer consumer business, but not a priority

GlaxoSmithKline's new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc's consumer products business, but would not overpay for the asset.

09 Jan 2018

GSK CEO says looking at Pfizer consumer business, but not a priority

GlaxoSmithKline's new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc's consumer products business, but would not overpay for the asset.

09 Jan 2018

GSK CEO says looking at Pfizer consumer business, but not a priority

Jan 9 GlaxoSmithKline's new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc's consumer products business, but would not overpay for the asset.

09 Jan 2018

Pfizer ends research for new Alzheimer's, Parkinson's drugs

(In this January 7 story corrects paragraph 3 to show that tanezumab is not yet on the market)

08 Jan 2018

CORRECTED-Pfizer ends research for new Alzheimer's, Parkinson's drugs

NEW YORK, Jan 7 Pfizer Inc is abandoning research to find new drugs aimed at treating Alzheimer's and Parkinson's disease, the U.S. pharmaceutical company announced on Saturday.

08 Jan 2018

BRIEF-Pfizer Announces Expiration, Results Of Tender Offer For Its 5.750 pct

* PFIZER INC. ANNOUNCES EXPIRATION AND RESULTS OF ITS TENDER OFFER FOR ITS 5.750 PER CENT. NOTES DUE 2021 AND RELATED SOLICITATION OF CONSENTS

08 Jan 2018

BRIEF-Pfizer Establishes New Partnering Model For Early-Stage Academic Research

* PFIZER ESTABLISHES NEW PARTNERING MODEL FOR EARLY-STAGE ACADEMIC RESEARCH Source text for Eikon: Further company coverage:

08 Jan 2018

BRIEF-Berkeley Lights Announces Research Collaboration And License Agreement With Pfizer

* BERKELEY LIGHTS ANNOUNCES RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH PFIZER Source text for Eikon: Further company coverage:

04 Jan 2018

Competitors

Earnings vs. Estimates